Hernández ANJ, Huerta VD, Castellanos DCL, Lozano NJJ, Huerta RS, Elizalde BCI, Melchor LA

Language: Spanish
References: 17
Page: 234-239
PDF size: 517.89 Kb.

ABSTRACT

Background: Sepsis is considered a public health problem and, due high cost of medical care, diverse prognoses models has been developed to estimate the disease severity and to help physicians in the treatment decisions. Objective: Compare two clinical scales (APACHE II, LODS) with biomarkers (lactate and eosinophils) as predictors of mortality.
Patients and method: Analytical cross-sectional, prospective and prolective study. Were included adult patients with sepsis diagnosis or septic shock hospitalized in the Internal Medicine service in hospitals of second level of care from Secretaría de Salud del Distrito Federal (SSDF). Lactate and eosinophils were quantified, as well as APACHE II and LODS scores, at income and in the follow-up 28 days later.
Results: There were no significant differences between the groups of patients with sepsis or septic shock in relation with age, sex, schooling or infectious focus. A concentration of lactate ≥ 1.8 mmol/L is a placeholder with greater certainty in diagnoses through an index of Pearson correlation (0.65).
Conclusions: lactate proved to be a biomarker that correlates directly with the mortality of patients with septic shock in relation to clinical scales that require higher inputs.

REFERENCES

1. Angus DC y col. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001;29:1303-1310.

2. Bone RC y col. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655.

3. Dellinger RP, y col. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock. Intensive Care Med 2008;34:17–60.

4. Parrillo JE, Parker MM, Natanson C, y col. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113:227–242.

5. Hollenberg SM. Vasopressor Support in Septic Shock. CHEST 2007;132:1678–1687.

6. Mikkelsen ME., y col. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med 2009;37:1670-1677.

7. Knaus WA: APACHE 1978–2001: the development of a quality assurance system based on prognosis: milestones and personal reflections. Arch Surg 2002;137:37-41.

8. Knaus WA, y col. APACHE II: a severity of disease classificationsystem. Crit Care Med 1985;13(10):818–29.

9. Le Gall JR. The use of severity scores in the intensive care unit. Intensive Care Med 2005;31(12):1618–1623.

10. Rivers EP y col. Improving Outcomes for Severe Sepsis and Septic Shock: Tools for early identification of at-risk patient and treatment protocol implementation. Crit Care Clin 2008;23:S1-S47.

11. Shapiro NI y col. Serum lactate as a pridictor of mortality in emergency departament patients with infection. Ann Emerg Med 2005;45:524-528.

12. Revelly JP y col. Lactate and glucose metabolism in severe sepsis and cardiogenic shock. Crit Care Med 2005:33:2235-2240.

13. Duke T. Dysoxia and lactate. Arch Dis Child 1999;81:343-350.

14. Bass DA y col. Eosinopenia of acute infection: production of eosinopenia by chemotactic factors of acute inflammation. J ClinInvest 1980;65:1265-1271.

15. Zappert J.Ueber das Vrolmmen der Eosinophilen Zellen in maneschlichen Blute. Z Klin Med 1893;23:227-308.

16. Gil H y col. Value of essinopenia in inflammatory disorders: an “old” marker revisted. Rev Med Interne 2003;24:431-435.

17. Abidi K y col. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Critical Care 2008;12:R59.